

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/587,052
Filing Date	04-09-2007
First Named Inventor	Bunn Jr.
Art Unit	1642
Examiner Name	AEDER, SEAN E
Attorney Docket Number	2848-65-PUS

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	-----------------------	--	-----------------------------	---	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² , Number ⁴ , Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1	WO 2004/063709	07/29/04	SQUIBB BRISTOL MYERS CO		
	2	WO 2005/067667	07/28/05	SQUIBB BRISTOL MYERS CO		
	3	WO 2005/094332	10/13/05	SQUIBB BRISTOL MYERS CO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	
	4	BASELGA et al., "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Five Selected Solid Tumor Types" Journal of Clinical Oncology, 2002, Vol. 20, No. 21, pages 4292-4302
	5	CHINNAIYAN ET AL. "Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition", Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings, Vol. 22, No. 14S, 3029
	6	DEEB ET AL., "Altered E-Cadherin and Epidermal Growth Factor Receptor Expressions are Associated with Patient Survival in Lung Cancer: A Study Utilizing High-Density Tissue Microarray and Immunohistochemistry", Modern Pathology, 2004, Vol. 17, pages 430-439

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SA/

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/587,052
Filing Date	04-09-2007
First Named Inventor	Bunn Jr.
Art Unit	1642
Examiner Name	AEDER, SEAN E
Attorney Docket Number	2848-65-PUS

Sheet	2	of	2
-------	---	----	---

7	WITTA ET AL., "Genes and Proteins Involved in Predicting Sensitivity/Resistance to Gefitinib in Lung Cancer", presented at the October 29, 2004 Meeting for the European Society for Medical Oncology (EMSO), 1 page
8	International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2005/002325, issued July 24, 2006 (Attorney's Ref. No. 2848-65-PCT)

Examiner Signature	/Sean Aeder/ (02/26/2008)	Date Considered	
-----------------------	---------------------------	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SA/